APP and Alzheimer disease: APP mutations that lead to increase of overall Aβ production such as KM670/671NL (Swedish) lead to elevation of both AD and CAA pathology, whereas mutations that shift Aβ42/Aβ40 ratio toward Aβ42 (for example, T714I–Austrian, V717I–London, etc.)trigger the pathological process toward AD.